SCHEMBL1862507

SCHEMBL1862507

Oc1ccc2ccccc2c1CNc1c2ccccc2nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 10/20 0.61
▸ MEN1 O00255 8/20 0.61
▸ KDM4E B2RXH2 8/20 0.61
▸ ALDH1A1 P00352 7/20 0.61
▸ GAA P10253 6/20 0.61
▸ MAPT P10636 5/20 0.61
▸ HPGD P15428 3/20 0.61
▸ ALOX12 P18054 2/20 0.61
▸ TDP1 Q9NUW8 2/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ POLB P06746 4/20 0.57
▸ RAD52 P43351 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ PHLPP2 Q6ZVD8 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ GLA P06280 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12531030 0.77 HSD17B10 (0.68) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL18313922 0.76 PKM (0.57) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL19982316 0.75 MEN1 (0.60) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL13219070 0.74 HSD17B10 (0.63) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL12305654 0.74 HSD17B10 (0.69) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL1868598 0.73 RAD52 (1.00) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL22750733 0.72 ELANE (0.67) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL3031458 0.72 ALDH1A1 (0.78) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL21163949 0.71 HSD17B10 (0.59) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL1866885 0.71 POLB (0.58) KMT2AMEN1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493857-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES Ariel-University Research and Development Company Ltd. (IL) 2012-09-05 — — EP claimed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 — — US claimed
WO-2011051950-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 2011-05-05 — — WO claimed
EP-2493857-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES Ariel-University Research and Development Company Ltd. (IL) 2012-09-05 — — EP disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 — — US disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 — — US disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 — — US disclosed
WO-2011051950-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 2011-05-05 — — WO disclosed
WO-2011051950-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES MPG, PRMT9, AADAT KMT2A 848/4885MEN1 1862/4885KDM4E 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback